Meta-Analysis of Capecitabine versus 5-Fluorouracil in Advanced Gastric Cancer

Table 1

Clinical characteristics of included literature.

First author	Year	Sample size (capecitabine/5-fluorouracil)	Age, years (capecitabine/5-fluorouracil)	Number of males (capecitabine/5-fluorouracil)	Capecitabine arm chemotherapy regimen	5-Fluorouracil arm chemotherapy regimen
Cunningham [8]	2008	494/508	63/63	392/393	Epirubicin/cisplatin/capecitabine, or epirubicin/oxaliplatin/capecitabine	Epirubicin/cisplatin/5-fluorouracil, or epirubicin/oxaliplatin/5-fluorouracil
Kang [9]	2009	139/137	56/56	103/108	Cisplatin/capecitabine	Cisplatin/5-fluorouracil
Li [10]	2016	55/50	52/52	35/34	Epirubicin/oxaliplatin/capecitabine	Irinotecan/5-fluorouracil/leucovorin calcium
Ochenduszko [11]	2015	29/27	58/60	16/13	Epirubicin/oxaliplatin/capecitabine	Docetaxel/cisplatin/5-fluorouracil
Ocvirk [12]	2012	40/45	56/55	32/34	Epirubicin/cisplatin/capecitabine	Epirubicin/cisplatin/5-fluorouracil
Sumpter [13]	2005	96/108	63/62	82/79	Epirubicin/cisplatin/capecitabine, or epirubicin/oxaliplatin/capecitabine	Epirubicin/cisplatin/5-fluorouracil, or epirubicin/oxaliplatin/5-fluorouracil
Tebbutt [14]	2010	47/53	59/61	42/42	Docetaxel/capecitabine	Docetaxel/cisplatin/5-fluorouracil
Van Cutsem [15]	2014	82/88	59/58	74/69	Docetaxel/oxaliplatin/capecitabine	Docetaxel/oxaliplatin/5-fluorouracil